UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to __________ (State or other jurisd ...

OptimizeRx Corporation (NASDAQ:OPRX) Q2 2021 Results Conference Call August 4, 2021 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Doug Baker - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Andrew D'Silva - B. Riley Securities Eric Martinuzzi - Lake Street Capital Harvey Poppel - Poptech, LP Operator Good afternoon and thank you for joining OptimizeRx Corporation's Secon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction o ...

NASDAQ:OPRX A Digital Health Platform Corporate Presentation May 2021 Physician Communications Patient Engagement Adherence © Copyright OptimizeRx, Inc. 2021 & 2020. All rights reserved NASDAQ : OPRX Important Cautions Regarding Forward Looking Statements This presentation has been prepared by OptimizeRx Corporation ("w e," "us," "our," "OptimizeRx" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shal ...

Financial Data and Key Metrics Changes - The company reported a revenue of $11.2 million for Q1 2021, representing a 48% increase compared to $7.6 million in Q1 2020 [31] - Gross margin decreased from 57% in Q1 2020 to 55% in Q1 2021, attributed to a change in solution mix [32] - Operating expenses increased slightly by 2.5% from $6.6 million in Q1 2020 to $6.8 million in Q1 2021, indicating strong operating leverage [34] - The net loss for Q1 2021 was $600,000 or $0.04 per share, an improvement from a net loss of $2.2 million or $0.15 per share in Q1 2020 [35] Business Line Data and Key Metrics Changes - The company closed 33 deals from a pipeline of 46 announced in the previous quarter, with client renewals totaling $25 million in annual contract value [13] - The average value of recently won contracts was close to $1 million, approximately three times higher than previous years [15] - The renewal rate exceeded 86%, driven by strong third-party ROI from previous programs [15] Market Data and Key Metrics Changes - The company expanded its omnichannel platform reach to over 50% of oncologists in the U.S., capitalizing on the fast-growing oncology segment projected to grow over 12% in 2021 [23] - The demand for real-world evidence solutions has increased significantly since the announcement in Q4 2020, indicating a transformative impact on therapeutic support delivery [26] Company Strategy and Development Direction - The company is focused on enhancing its digital health platform and expanding its core capabilities to support future revenue streams [8] - A land and expand strategy is being employed to penetrate more clients and increase engagement with existing solutions [14] - The management team is committed to diversity, equity, and inclusion, establishing an internal committee to foster a welcoming corporate culture [40] Management's Comments on Operating Environment and Future Outlook - The management expressed confidence in the strong start to 2021, anticipating continued growth throughout the year [21] - The company is well-positioned to capture additional recurring revenue as COVID vaccinations increase demand for healthcare services [19] - The digital transformation in the industry is expected to drive ongoing growth, with a focus on improving physician-patient engagement [20] Other Important Information - The company raised $71 million through a public offering in February, strengthening its balance sheet for strategic goals and potential M&A activities [17] - Cash and cash equivalents totaled $83 million at the end of Q1 2021, a significant increase from $10.5 million at the end of 2020 [37] Q&A Session Summary Question: Insights on the $15 million remaining in the enterprise pipeline - Management expressed confidence in closing the remaining $15 million in deals, with most expected to contribute to 2021 revenue [49] Question: Evolution of the business post-Q1 with increased vaccinations - Management noted that life science companies are still primarily virtual and not yet engaging in live interactions, indicating a shift in marketing strategies [54][56] Question: Other specialties for growth beyond oncology - The company is also focusing on cardiology and other therapeutic areas, leveraging digital enablement trends [58] Question: Transition of EHRs to cloud-based platforms - Management confirmed a continued push towards cloud-based platforms, enhancing connectivity and partnerships beyond traditional EHRs [68] Question: Progress on non-enterprise business and win rates - The company reported win rates between 35% and 50% for non-enterprise deals, with encouraging conversion rates overall [76] Question: Expanded recurring revenue stream characterization - Management indicated that enterprise recurring revenue is expected to grow from $20 million last year to $40 million this year, reflecting strong client engagement [89] Question: Future operating expenses and investment areas - Operating expenses are expected to increase at a lower rate than revenue growth, with investments focused on client satisfaction and technology [98]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) | Nevada | 26-1265381 | | --- | --- | | (State or other ...

OptimizeRx Corporation. (NASDAQ:OPRX) Q4 2020 Results Earnings Conference Call February 24, 2021 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Doug Baker - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Miriam Paramore - President Conference Call Participants Ryan Daniels - William Blair Andrew D'Silva - B. Riley Securities Eric Martinuzzi - Lake Street Harvey Poppel - Poptech, LP Siddharth Kapoor - Silver Mount Capital. Operator Good afternoon, and thank you ...

NASDAQ:OPRX A Digital Health Platform Corporate Presentation November 2020 Physician Communications Patient Engagement Adherence © Copyright OptimizeRx, Inc. 2020 & 2019. All rights reserved NASDAQ : OPRX Important Cautions Regarding Forward Looking Statements This presentation has been prepared by OptimizeRx Corporation ("we," "us," "our," "OptimizeRx" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor ...

OptimizeRx Corporation (NASDAQ:OPRX) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Doug Baker - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Miriam Paramore - President Conference Call Participants Andrew D'Silva - B. Riley FBR, Inc. Ryan Daniels - William Blair & Company, L.L.C. Richard Baldry - ROTH Capital Partners, LLC Eric Martinuzzi - Lake Street Capital Markets, LLC Josh Goldberg - G2 Investment Partne ...